

Date: October 09, 2020

To,
Ms. Kruti Shah,
Surveillance
BSE Limited
Phiroze Jeejeeboy Towers,
Dalal Street, Mumbai- 400001

Dear Sir,

Sub: Clarification on Price Movement

With reference to your letter No. L/SURV/ONL/PV/NJ/2020-2021/2617 dated 09-10-2020 sent to us by mail, we wish to inform you as follows:

1) We have submitted a business update giving you the brief details of the performance of the company in the quarter ending 30th September 2020, explaining how the Covid-19 pandemic and the consequent lock down had a negative impact on our business and how our business has recovered from the negative impact, thanks to the increase in volume of Covid-19 RT-PCR tests and Covid-19 Antibody tests, and the steady rise in non-Covid 19 business as well.

2) We had also mentioned that unaudited results for the quarter ended 30th September 2020 were under the review of our Auditors and would be filed after approval by Audit Committee and the Board of Directors.

3) We had also mentioned that we are unable to communicate with our shareholders in an effective manner, as also meet their queries, especially on account of minimum participation at the recent virtual Annual General Meeting; therefore, in terms of the Clauses 30 & 36 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we were apprising you and all our shareholders / stakeholders of the above material developments having a bearing on our performance / operations / finance, which information we consider as 'price sensitive' concerning our listed securities.

Please note that apart from the above, there is no other price-sensitive information / announcement or impending announcement, which, in our opinion, may have a bearing on the price / volume behaviour in the scrip, which has not been disclosed to the Exchanges.

We shall ensure to let the investors have latest relevant information about our company in time.

We shall further ensure, as always, to provide you timely and without fail such information /announcement (including impending announcement) which in our opinion may have a bearing on the price / volume behavior in the scrip, in the interest of investors, as and when occasions arise.

Yours faithfully,

For Thyrocare Technologies Limited,

Ramjee Dorai
Company Secretary & Compliance Officer



Thyrocare Technologies Limited